Drug intelligence / Profile preview

YH14642

Development stage: Phase 2
Lead developer: Yuhan
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

**YH14642** is an orally administered herbal medicinal candidate developed by Yuhan for chronic periodontitis. It is a water-extract preparation derived from Notoginseng Radix and Rehmanniae Radix Preparata. In a randomized, double-blind Phase II study in South Korea, it was evaluated over 12 weeks for chronic periodontal disease; subsequent preclinical work reported suppression of lipopolysaccharide-stimulated interleukin-6 and interleukin-8 secretion in human gingival fibroblasts. Its precise molecular target and active constituent profile have not been publicly defined.

Beyond the preview

Go deeper on YH14642.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YH14642.

Explore the full profile